Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis
dc.contributor.author | Tzioras, S. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Paraskevaidis, E. | en |
dc.contributor.author | Ioannidis, J. P. A. | en |
dc.creator | Tzioras, S. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Paraskevaidis, E. | en |
dc.creator | Ioannidis, J. P. A. | en |
dc.date.accessioned | 2018-06-22T09:53:23Z | |
dc.date.available | 2018-06-22T09:53:23Z | |
dc.date.issued | 2007 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41814 | |
dc.description.abstract | Background: A large number of trials have assessed various chemotherapy regimens for the treatment of advanced cervical cancer, but there is uncertainty about the magnitude of survival benefits. Methods: We searched (last update January 2006) for trials in women with locally advanced or disseminated cervical cancer that compared neo-adjuvant or concurrent chemotherapy plus radiotherapy versus radiotherapy alone; or different chemotherapy regimens among themselves (with or without background radiotherapy in both arms). Sixty-five trials were identified with survival data on 11,180 women. Results for survival were combined with fixed and random effects models and between-study heterogeneity was estimated. Separate results were obtained for different regimens, cycle length, and type of chemotherapy (neo-adjuvant, concurrent, without radiotherapy). Results: Twenty two comparisons had survival data on 3837 women randomized to receive chemotherapy plus radiotherapy versus radiotherapy alone; the summary relative hazard for mortality was 0.95, 95% CI, 0.83-1.08. Modest between-study heterogeneity (I2 = 38%) seemed to be due to contradictory results in early trials; trials published in the last decade had a summary relative hazard 0.89 (95% CI, 0.78-1.02) and no between-study heterogeneity (I2 = 0%). Results were similar for neo-adjuvant chemotherapy and for concurrent chemo-radiotherapy. Cisplatin or cisplatin-based combinations had no significant benefit overall, but a potential benefit was seen with short-length cycles (≤14 days) and a marginally significant harm with longer-length cycles (summary relative hazards 0.80, 95% CI, 0.66-0.99 and 1.18, 95% CI, 1.02-1.38, respectively). The summary relative hazard was 1.02, (95% CI, 0.84-1.24) for trials using neo-adjuvant chemotherapy and 0.85 (95% CI, 0.73-1.00) for trials using concurrent chemotherapy. Conclusions: Evidence on chemotherapy in women with advanced cervical cancer is not encouraging for major survival benefits. However, small benefits have been observed in some trials, especially with short-length cycles of cisplatin-based regimens and concurrent chemotherapy and radiotherapy. © 2006. | en |
dc.language.iso | eng | en |
dc.source | Cancer treatment reviews | en |
dc.subject | Female | en |
dc.subject | Meta-analysis | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Bleomycin | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Doxorubicin | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Hydroxyurea | en |
dc.subject | Methotrexate | en |
dc.subject | Mitomycin | en |
dc.subject | Vinblastine | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Chemotherapy | en |
dc.subject | Paclitaxel | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Gemcitabine | en |
dc.subject | Monotherapy | en |
dc.subject | Topotecan | en |
dc.subject | Survival analysis | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Review | en |
dc.subject | Metastasis | en |
dc.subject | Survival | en |
dc.subject | Systematic review | en |
dc.subject | Epirubicin | en |
dc.subject | Lomustine | en |
dc.subject | Platinum complex | en |
dc.subject | Uterine cervix cancer | en |
dc.subject | Meta analysis | en |
dc.subject | Mitomycin c | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Survival time | en |
dc.subject | Placebo | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Ifosfamide | en |
dc.subject | Altretamine | en |
dc.subject | Platinum compounds | en |
dc.subject | Uterine cervical neoplasms | en |
dc.subject | Combination chemotherapy | en |
dc.subject | Combined modality therapy | en |
dc.subject | Chlorambucil | en |
dc.subject | Amifostine | en |
dc.subject | Advanced stage | en |
dc.subject | Vindesine | en |
dc.subject | Teniposide | en |
dc.subject | Cervical cancer | en |
dc.subject | Doxifluridine | en |
dc.subject | Iproplatin | en |
dc.subject | Mitolactol | en |
dc.subject | Randomized controlled trials | en |
dc.title | Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.ctrv.2006.09.007 | |
dc.description.volume | 33 | |
dc.description.issue | 1 | |
dc.description.startingpage | 24 | |
dc.description.endingpage | 38 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |